RADAY GILEAD

PrivateCIK: 2113137

RADAY GILEAD enters REDHILL BIOPHARMA LTD. with 307.58M shares plus derivative instruments

Holding both equity and derivatives at entry signals strong long-term conviction in the company.

Direct Derivatives
InsiderRADAY GILEADCIK 2113137
IssuerREDHILL BIOPHARMA LTD.CIK 1553846
Officer· Chief Operating Officer
Since Mar 2026
307.58M
Baseline shares
100% direct
307.58M
Direct ownership
1 position
47.37M
Derivative underlying
6 instruments
1
Security positions
All direct
Non-Derivative Holdings1

Ordinary Shares

Direct
Shares owned307.58M
Total
307.58M direct307.58M
Derivative Holdings6

Stock Option (Right to Buy)

Direct
Underlying security
Ordinary Shares

Underlying shares

600K

Shares owned

N/A

Exercise price

Expiration

Exercise window

Stock Option (Right to Buy)

Direct
Underlying security
Ordinary Shares

Underlying shares

400K

Shares owned

N/A

Exercise price

Expiration

Exercise window

Stock Option (Right to Buy)

Direct
Underlying security
Ordinary Shares

Underlying shares

250K

Shares owned

N/A

Exercise price

Expiration

Exercise window

Stock Option (Right to Buy)

Direct
Underlying security
Ordinary Shares

Underlying shares

180K

Shares owned

N/A

Exercise price

Expiration

Exercise window

American Depositary Shares

Direct
Underlying security
Ordinary Shares

Underlying shares

45.37M

Shares owned

N/A

Exercise price

Expiration

Exercise window

Stock Option (Right to Buy)

Direct
Underlying security
Ordinary Shares

Underlying shares

570K

Shares owned

N/A

Exercise price

Expiration

Exercise window

Total

Underlying

47.37M

Owned

0.00

RADAY GILEAD — Initial Ownership Disclosure (Form 3) Filed Mar 18, 2026 | Finecho